Hand drug pharmaceutical health Colin Campbell/Flickr

Buy Back or Pay Forward?

The pharmaceutical industry likes to argue that companies need to be guaranteed a robust return on investments if they are to invest in new treatments. And yet there is a good reason why drug firms should help solve the problem of antimicrobial resistance: enlightened self-interest.

LONDON – When British Prime Minister David Cameron asked me to lead a review into the problem of antimicrobial resistance, the last thing I expected was that accepting the position would lead me to question one of the most popular tools for corporate financial management: share buybacks.

The problem of antimicrobial resistance is a serious one. Left unaddressed, it could be responsible by 2050 for the deaths of some ten million people a year, more than currently die of cancer, along with an astonishing $100 trillion in economic damage. Fortunately, however, there is much we can do to mitigate the threat – provided that adequate resources are made available.

One important avenue to pursue is the development of new drugs. In a forthcoming paper, the Review on Antimicrobial Resistance estimates that bringing new antimicrobials to market and improving their administration will cost about $25 billion – a significant sum, but one that pales in comparison to the costs to society if the problem is not checked. It is also roughly what two of the world’s largest pharmaceutical companies will spend this year buying back their own shares.

We hope you're enjoying Project Syndicate.

To continue reading, subscribe now.

Subscribe

Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.

http://prosyn.org/8s7MpZV;
  1. solana105_JUANMABROMATAAFPGettyImages Juan Mabromata/AFP/Getty Images

    The Lost Spirit of the G20

    Javier Solana

    As Japan prepares to host its first G20 leaders’ summit later this month, little remains of the open and cooperative spirit that marked the first such gathering in 2008. But although the United States will most likely continue its protectionist drift, other G20 countries should use the occasion to make a clear case for free trade.

  2. velasco94_YoustGettyImages_headswithbooksstaring Youst/Getty Images

    The Experts We Need

    Andrés Velasco

    Policy gurus spend too much time with others like them – top civil servants, high-flying journalists, successful businesspeople – and too little time with ordinary voters. If they could become “humble, competent people on a level with dentists,” as John Maynard Keynes once suggested, voters might identify with them and find them trustworthy.

  3. benami152_KiyoshiOtaPoolGettyImages_trumpmelaniaeatinginJapan Kiyoshi Ota - Pool/Getty Images

    Don’t Feed the Donald

    Shlomo Ben-Ami

    For Japanese Prime Minister Shinzo Abe, appeasing US President Donald Trump is not so much a choice as a necessity: he must prove to Japan’s people and their neighbors, particularly the Chinese, that he knows how to keep Trump on his side. But Abe's strategy won't work with a US administration as fickle and self-serving as Trump’s.

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.